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Abstract
Background: Adrenomedullin (ADM) regulates vascular tone and endothelial permeability during sepsis. Levels
of circulating biologically active ADM (bio-ADM) show an inverse relationship with blood pressure and a
direct relationship with vasopressor requirement. In the present prospective observational multinational
Adrenomedullin and Outcome in Sepsis and Septic Shock 1 (, AdrenOSS-1) study, we assessed relationships
between circulating bio-ADM during the initial intensive care unit (ICU) stay and short-term outcome in order
to eventually design a biomarker-guided randomized controlled trial.
Methods: AdrenOSS-1 was a prospective observational multinational study. The primary outcome was 28-day
mortality. Secondary outcomes included organ failure as defined by Sequential Organ Failure Assessment
(SOFA) score, organ support with focus on vasopressor/inotropic use, and need for renal replacement therapy.
AdrenOSS-1 included 583 patients admitted to the ICU with sepsis or septic shock.
(Continued on next page)
* Correspondence: alexa.hollinger@usb.ch
†Christopher Geven and Alexa Hollinger contributed equally to this work.
1Department of Anesthesiology, Burn and Critical Care Medicine, AP-HP,
Saint Louis and Lariboisière University Hospitals, 2 rue A. Paré, 75010 Paris,
France
2Inserm 942, Paris, France
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mebazaa et al. Critical Care          (2018) 22:354 
https://doi.org/10.1186/s13054-018-2243-2
(Continued from previous page)
Results: Circulating bio-ADM levels were measured upon admission and at day 2. Median bio-ADM
concentration upon admission was 80.5 pg/ml [IQR 41.5–148.1 pg/ml]. Initial SOFA score was 7 [IQR 5–10],
and 28-day mortality was 22%. We found marked associations between bio-ADM upon admission and 28-day
mortality (unadjusted standardized HR 2.3 [CI 1.9–2.9]; adjusted HR 1.6 [CI 1.1–2.5]) and between bio-ADM
levels and SOFA score (p < 0.0001). Need of vasopressor/inotrope, renal replacement therapy, and positive
fluid balance were more prevalent in patients with a bio-ADM > 70 pg/ml upon admission than in those
with bio-ADM ≤ 70 pg/ml. In patients with bio-ADM > 70 pg/ml upon admission, decrease in bio-ADM
below 70 pg/ml at day 2 was associated with recovery of organ function at day 7 and better 28-day
outcome (9.5% mortality). By contrast, persistently elevated bio-ADM at day 2 was associated with prolonged
organ dysfunction and high 28-day mortality (38.1% mortality, HR 4.9, 95% CI 2.5–9.8).
Conclusions: AdrenOSS-1 shows that early levels and rapid changes in bio-ADM estimate short-term outcome in
sepsis and septic shock. These data are the backbone of the design of the biomarker-guided AdrenOSS-2 trial.
Trial registration: ClinicalTrials.gov, NCT02393781. Registered on March 19, 2015.
Keywords: Biomarker, Outcome, Sepsis-2, Sepsis-3
Introduction
Adrenomedullin (ADM) is a free circulating peptide with
potent vascular properties, including benefits for endothe-
lial barriers at physiological levels. ADM has previously
been described as a “double-edged sword” in sepsis [1]
because high levels of ADM induce vasodilation and
hypotension [2–4] on one hand while reinforcing the
endothelial barrier and improving outcome on the other
[5–10]. The potential of ADM as a prognostic biomarker
has previously been studied in critically ill patients, often
by measuring the inactive midregional pro-ADM [11, 12],
or recently by direct measurement of the bioactive form
of ADM (bio-ADM) [13, 14]. It has been shown repeat-
edly that bio-ADM greater than 70 pg/ml is associated
with worse outcome [13, 14].
On the basis of previous results, we tested the hypoth-
esis that modulating the ADM pathway in patients with
high levels of circulating bio-ADM may improve short-
term outcome in sepsis. Adrecizumab, a monoclonal
anti-ADM antibody, has been shown to improve organ
function in preclinical settings [15]. In order to design a
human trial in which we would administer adrecizumab
based on levels of bio-ADM, we needed to assess the rela-
tionship between initial levels of bio-ADM and short-term
outcome in sepsis and in septic shock patients.
In the Adrenomedullin and Outcome in Sepsis and
Septic Shock 1 (AdrenOSS-1) study, we investigated
whether the initial plasma concentration of bio-ADM
(on intensive care unit [ICU] admission and after 48 h)
may provide insight into 28-day survival and the recov-
ery of organ function.
Methods
Study design
AdrenOSS-1 was a European prospective observational
study. Twenty-four centers in five countries (France,
Belgium, The Netherlands, Italy, and Germany) contrib-
uted to the trial achievement of 583 enrolled patients.
Patients were recruited from June 2015 to May 2016. The
study protocol was approved by the local ethics commit-
tees and was conducted in accordance with Directive
2001/20/EC, as well as good clinical practice (Inter-
national Conference on Harmonization Harmonized Tri-
partite Guideline version 4 of May 1, 1996, and decision
of November 24, 2006) and the Declaration of Helsinki.
The study enrolled patients aged 18 years and older
who were (1) admitted to the ICU for sepsis or septic
shock or (2) transferred from another ICU in the state
of sepsis and septic shock within less than 24 h after
admission. Included patients were stratified by severe
sepsis and septic shock based on definitions for sepsis
and organ failure from 2001 [16]. In the present article,
the term “sepsis” refers to the updated definition of
Sepsis-3 [17]. Concerning septic shock, most data pre-
sented in this article are based on the former definition
[16], except for the confirmatory analyses presented in
the last paragraph of the “Results” section, for which the
new Sepsis-3 definition of septic shock was used [17].
Exclusion criteria were pregnancy, vegetative coma, and
participation in an interventional trial in the preceding
month. Informed consent was obtained from all patients
or their lawful representatives prior to enrollment in the
study. Patients were treated according to local practice,
and treatments as well as procedures were registered.
The primary endpoint was 28-day mortality. Secondary
endpoints concerned organ failure (as defined by the
Sequential Organ Failure Assessment [SOFA] score) and
organ support, vasopressor/inotrope use, fluid balance,
and use of renal replacement therapy (RRT), as well as val-
idation of the previously identified cutoff value of 70 pg/
ml [14]. The latter was identified as the optimal screening
cutoff for AdrenOSS-2, an ongoing proof-of-concept and
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dose-finding phase II trial assessing adrecizumab (an anti-
body modulating circulating bio-ADM) in patients with
early septic shock (NCT03085758). The relationship be-
tween cardiovascular SOFA subscore and bio-ADM, being
a biomarker of vascular dysfunction, was evaluated.
Collection of patient data
Upon admission, demographics (age, sex), body mass
index, presence of septic shock, type of ICU admission,
organ dysfunction scores (SOFA, Acute Physiologic As-
sessment and Chronic Health Evaluation II [APACHE II]),
origin of sepsis, preexisting comorbidities (i.e., treated
within the last year), past medical history, laboratory
values, and organ support were recorded, and blood was
drawn for measurement of bio-ADM and other markers.
After patient enrollment, the following data were col-
lected daily during the first week: SOFA score, anti-
microbial therapies, fluid balance, ventilation status,
Glasgow Coma Scale score, central venous pressure,
need for RRT, invasive procedures for sepsis control, and
vasopressor/inotrope treatment. Moreover, discharge
status and mortality were recorded on day 28 after ICU
admission.
Sample collection
Blood for the central laboratory was sampled within
24 h after ICU admission and on day 2 (mean 47 h, SD
9 h) after the first sample. Samples were subsequently
processed and stored at − 80 °C before transfer to the
central laboratory for blinded bio-ADM analysis organized
by the study sponsor (sphingotec GmbH, Hennigsdorf,
Germany). Routine analyses (e.g., partial pressure of
arterial oxygen, lactate) were performed by the local
laboratories.
Bio-ADM measurement
Bio-ADM was measured using a recently developed im-
munoassay provided by sphingotec GmbH. For details
and design principles on the assay, see publications by
Marino et al. [14] and Weber et al. [18]. The analytical
assay sensitivity was 2 pg/ml.
Statistical analyses
Results are presented as number and percentage, mean
and SD, or median and IQR, depending on their distri-
bution. Group comparisons for continuous variables
were performed using the Kruskal-Wallis test, and ap-
propriate post hoc tests were applied if necessary. Cat-
egorical data were compared using the chi-square test
with simulated p values using 2000 replicates. Biomarker
data were log-transformed if necessary. Cox proportional
hazards regression was used to analyze the effect of risk
factors on survival in uni- and multivariable analyses.
The assumptions of proportional hazards were tested for
all variables. For continuous variables, HRs were stan-
dardized to describe the HR for a biomarker change of
one IQR. CIs (95% CI) for risk factors and significance
levels for chi-square (Wald) test are given. The predict-
ive value of each model was assessed by the model likeli-
hood ratio chi-square statistic. The concordance index
(C index) is given as an effect measure. It is equivalent
to the concept of AUC adopted for binary outcome. For
multivariable models, a bootstrap-corrected version of
the C index is given. To test for added predictive value,
we used the likelihood ratio chi-square test for nested
models to assess whether bio-ADM adds predictive
value to a clinical model or a risk score. Survival curves
plotted by the Kaplan-Meier method using quartiles or
predefined cut points (70 pg/ml) of bio-ADM were used
for illustrative purposes. ROC curve analysis was applied
for 28-day mortality to determine the optimal Youden
cutoff in this cohort.
A two-sided p value of 0.05 was considered statistically
significant. All analyses were performed using R version
2.5.1 (http://www.r-project.org, library Design, Hmisc,
ROCR) and IBM SPSS Statistics version 22.0 software
(IBM, Armonk, NY, USA).
Results
A total of 583 patients were included in the AdrenOSS-1
study. Patient characteristics, organ dysfunction scores,
physiological and laboratory values, organ support upon
admission, and outcome parameters are presented in
Table 1. The median bio-ADM level at admission was
80.5 pg/ml [IQR 41.6–148.1] in our studied patients;
55.9% had bio-ADM level greater than 70 pg/ml at admis-
sion, and 44.1% had a bio-ADM less than 70 pg/ml. Of
note, patients with septic shock had a significantly higher
bio-ADM concentration at admission than patients with
sepsis (114.4 [62.6–214.5] versus 57.5 pg/ml [31.2–101.5],
p < 0.0001).
Bio-ADM levels and mortality
Over the 28-day follow-up period, 127 patients (22%)
died: 33 with sepsis and 94 with septic shock.
In a Cox proportional hazards model adjusted for age,
gender, comorbidities (cardiac and noncardiac), lactate,
and diagnosis (sepsis, septic shock), bio-ADM concen-
tration at admission was independently associated with
28-day mortality in the studied population (added
chi-square 12.2, p = 0.0005; adjusted standardized HR
1.6 [95% CI 1.1–2.5], p = 0.0004) (Table 2). Noticeably,
the C index for prediction of 28-day mortality for
bio-ADM at admission was 0.688 (95% CI 0.642–0.733,
chi-square 54.8, p < 0.0001) in the univariate Cox regres-
sion. C indexes for lactate, SOFA, and APACHE II were
0.720 (95% CI 0.672–0.768), 0.728 (95% CI 0.680–0.777),
and 0.701 (95% CI 0.657–0.746), respectively (all p <
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Table 1 Patient characteristics
Patient characteristics All Bio-ADM< 70 pg/ml
at admission
Bio-ADM> 70 pg/ml at admission p Value* No.
Epidemiological data n = 583 n = 257 n = 326
Bio-ADM at admission (pg/ml) 80.5 [41.5–148.0] 36.9 [27.1–51.0] 136.7 [97.6–241.0] < 0.0001
Age (years) 66 [55–76] 64 [53–75] 67 [58–76] 0.0052
Male sex (n, %) 364 (62.4) 171 (66.5) 193 (59.2) 0.0837
Body mass index (kg/m2) 25.7 [22.9–30.1] 25.0 [22.3–28.4] 26.7 [23.2–31.6] 0.0013
Septic shock at admission 293 (50.3) 84 (32.7) 209 (64.1) < 0.0001
Type of ICU admission < 0.0001
Medical 473 (81.1) 230 (89.5) 243 (74.5)
Surgical - emergency procedure 93 (16) 21 (8.2) 72 (22.1)
Surgical - elective procedure 17 (2.9) 6 (2.3) 11 (3.4)
Origin of sepsis < 0.0001
Lung 218 (37.4) 129 (50.2) 89 (27.3)
Bloodstream 90 (15.4) 31 (12.1) 59 (18.1)
Urinary tract 62 (10.6) 10 (3.9) 52 (16)
Catheter 29 (5) 9 (3.5) 20 (6.1)
Peritonitis 31 (5.3) 12 (4.7) 19 (5.8)
Endocarditis 31 (5.3) 12 (4.7) 19 (5.8)
Bile duct infection 8 (1.4) 2 (0.8) 6 (1.8)
CNS 4 (0.7) 4 (1.6) 0 (0)
Skin and soft tissue 10 (1.7) 9 (3.5) 1 (0.3)
Gynecologic 2 (0.3) 1 (0.4) 1 (0.3)
Other 98 (16.8) 38 (14.8) 60 (18.4)
Medical historya
Any cardiac comorbidity 400 (68.6) 147 (57.2) 253 (77.6) < 0.0001
Chronic heart failure 60 (10.3) 19 (7.4) 41 (12.6) 0.0544
Hypertension 293 (50.3) 105 (40.9) 188 (57.7) < 0.0001
Diabetes mellitus 160 (27.4) 57 (22.2) 103 (31.6) 0.0150
Any noncardiac comorbidity 414 (71) 167 (65) 247 (75.8) 0.0058
Chronic renal disease 76 (13.0) 19 (7.4) 57 (17.5) 0.0004
Active/recent malignant tumors 124 (21.3) 34 (13.2) 90 (27.6) < 0.0001
Smoking (active) 117 (20.1) 63 (24.5) 54 (16.6) 0.0302
COPD 89 (15.3) 37 (14.4) 52 (16.0) 0.6421
Any chronic medication 371 (63.6) 138 (53.7) 233 (71.5) < 0.0001
Immunosuppressive therapy 46 (7.9) 11 (4.3) 35 (10.7) 0.0066
Physiological values at admission
Temperature (°C) 37.2 [36.4–38.2] 37.4 [36.6–38.2] 37.1 [36.2–38.1] 0.0034
Mean blood pressure (mmHg) 75 [64–90] 81 [69–95] 72 [60–85] < 0.0001
Heart rate (beats/min) 104 [90–119] 100 [86–116] 105 [94–121] 0.0013
Central venous pressure (mmHg) 8 [5–13] 8 [5–13] 10 [6–14] 0.2419
Glasgow Coma Scale score 15 [14–15] 15 [14–15] 15 [14–15] 0.8161
Fluid balance (ml) 1928 [592–3552] 1425 [500–2699] 2311 [764–4202] < 0.0001
Urine output for 24 h (ml) 1000 [450–1900] 1276 [650–2050] 800 [300–1650] < 0.0001
PaO2/FiO2 228 [137–340] 233.5 [140–360] 223 [137–337] 0.4995
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0.0001). A multivariate model further demonstrated that
bio-ADM had added value on top of APACHE II or
SOFA score (added chi-square 24.4 [p < 0.0001] and 10.2
[p = 0.0014], respectively) (Table 2) when used as a con-
tinuous variable.
With the predefined cutoff value of 70 pg/ml, Kaplan-
Meier analysis confirmed predictive value of bio-ADM
for 28-day mortality in all studied patients (Additional
file 1: Figure S1) and in subgroups of sepsis and septic
shock (Fig. 1a and b). Patient characteristics for high
and low bio-ADM levels are illustrated in Table 1, and
characteristics for survivors versus nonsurvivors are pro-
vided in Additional file 2: Table S1. The optimal Youden
cutoff in all patients was 101.9 pg/ml (sensitivity 67.7%,
specificity 67.3%). In septic shock, the optimal Youden
cutoff was 99.1 pg/ml (sensitivity 71.3%, specificity 52.3%),
and in severe sepsis it was 101.9 pg/ml (sensitivity 57.6%,
specificity 78.6%). This compares with a sensitivity of
77.2% and specificity of 48.9% in all patients for the prede-
fined bio-ADM cutoff of 70 pg/ml.
We additionally assessed outcome in relation to
bio-ADM changes in the initial 48 h in time-dependent
Table 1 Patient characteristics (Continued)
Patient characteristics All Bio-ADM< 70 pg/ml
at admission
Bio-ADM> 70 pg/ml at admission p Value* No.
Laboratory values at admission
Lactate (mmol/L) 1.4 [1.0–2.2] 1.1 [0.8–1.6] 1.8 [1.2–2.7] < 0.0001 n = 562
Arterial pH 7.38 [7.3–7.44] 7.42 [7.36–7.46] 7.36 [7.27–7.42] < 0.0001
Bilirubin (μmol/L) 11 [6–19] 10 [6.5–17] 12 [6–21] 0.1360
Platelets (109/L) 190 [121–275] 196 [136–279] 181 [104–271] 0.0583
Creatinine (mg/dl) 1.4 [0.9–2.2] 1 [0.7–1.4] 1.8 [1.2–2.9] < 0.0001
BUN or urea (mg/dl) 61 [37–107] 44 [28–69] 80 [50–127] < 0.0001
Hematocrit (%) 34 [29–38] 35 [30–38] 34 [29–38] 0.1010
White blood cell count (per mm3) 12,525 [7200–18,585] 13,000 [8475–18,075] 12,025 [5942–19,025] 0.0547
Troponin T, maximum on day 1 42 [18–158] 29 [14–124] 55 [25–176] 0.0230 n = 153
Troponin I, maximum on day 1 69 [20–246] 40 [11–228] 99 [40–289] 0.0049 n = 186
PCT, maximum on day 1 (ng/ml) 11.4 [1.9–49.8] 3.9 [0.9–19.5] 24 [6–84] < 0.0001 n = 330
PCT, central laboratory (ng/ml) 10.2 [2.3–34.3] 3.7 [0.8–13.0] 18.2 [6.0–52.7] < 0.0001 n = 583
BNP, maximum on day 1 257 [102–723] 187 [61–388] 473 [147–1154] 0.0004 n = 131
NT-proBNP, maximum on day 1 4382 [1525–11,565] 2170 [497–6633] 6116 [2816–15,431] 0.0001 n = 117
Organ support at admission
Mechanical ventilation 0.0739
Invasive 219 (37.6) 85 (33.1) 134 (41.1)
Noninvasive 131 (22.5) 67 (26.1) 64 (19.6)
None 233 (40.0) 105 (40.9) 128 (39.3)
Renal replacement therapy 49 (8.4) 8 (3.1) 41 (12.6) 0.0001
Vasopressors/inotropes at admission 349 (59.9) 109 (42.4) 240 (73.6) < 0.0001
Organ dysfunction scores
SOFA (points) 7 [5–10] 5 [3–8] 8 [6–11] < 0.0001 n = 509
APACHE II (points) 15 [11–20] 14 [9–17] 18 [13–22] < 0.0001
Length of stay (days)
ICU 5 [2–10] 4 [2–8] 5 [2–10] 0.0554
Mortality
28-day, deaths (%) 127 (21.8) 30 (11.7) 97 (29.8) < 0.0001
90-day, deaths (%) 166 (28.5) 41 (16) 125 (38.3) < 0.0001
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, bio-ADM Bioactive adrenomedullin, BNP Brain-derived natriuretic peptide, BUN Blood urea
nitrogen, CNS Central nervous system, COPD Chronic obstructive pulmonary disease, ICU Intensive care unit, NT-proBNP N-terminal brain natriuretic peptide, PaO2/
FiO2 Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, PCT Procalcitonin, SOFA Sequential Organ Failure Assessment
* p Value from nonparametric Kruskal-Wallis or chi-square test, respectively
a Most common comorbidities reported individually
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Cox regression. Bio-ADM trajectory over the initial 48 h
after study inclusion improved prediction of 28-day
survival in the overall population (added chi-square 25.8,
p < 0.0001) (Table 2; Fig. 2, Additional file 3: Figure S2)
and was independent of time-dependent lactate or SOFA
score evaluation (Table 2). Patients were divided into
four groups based on baseline and day 2 bio-ADM
concentrations and under implementation of the cutoff
value of 70 pg/ml: remaining low (low-low, LL), high-to-
low (HL), low-to-high (LH), and remaining high (high-high,
HH). Patient characteristics of these subgroups are pre-
sented in Additional file 4: Table S2.
In patients admitted with high bio-ADM upon admis-
sion, those who decreased bio-ADM towards normal
values within the first 48 h (HL group) had a similar
28-day mortality to the LL group (HL 9.5%, LL 10.5%)
and a more favorable outcome than patients whose bio-
ADM remained high (HH group) or became high
(LH group) (28-day mortality of 38.1% and 38.2%)
(Additional file 4: Table S2).
Bio-ADM levels and organ dysfunction
Bio-ADM levels upon admission correlated with the ini-
tial SOFA score in all studied patients (n = 509, r = 0.49,
p < 0.0001) (Additional file 5: Figure S3). SOFA score
was higher in patients in septic shock than in those in
sepsis, and for each group in patients with high initial
bio-ADM (Additional file 6: Figure S4). Figure 3a indi-
cates that the initial level of circulating bio-ADM relates
to the need for and duration of organ support in survi-
vors (p < 0.0001).
Concerning circulating bio-ADM levels and cardiovas-
cular function, we found an almost linear relationship of
bio-ADM and both cardiovascular SOFA subscore (p <
Table 2 Association between bio-ADM and 28-day mortality
Variables Chi-square added chi-square p Value (added value) Std. HR bio-ADM p Value
bio-ADM (univariate) 54.8 2.3 [1.9–2.9] < 0.0001
Adjusted for SOFA at admission 85.1 10.2 0.0014 1.6 [1.2–2.1] 0.0014
Adjusted for APACHE II at admission 88.9 24.4 < 0.0001 1.9 [1.5–2.4] < 0.0001
Adjusted for covariates 132.1 12.2 0.0005 1.6 [1.1–2.5] 0.0004
bio-ADM (time-dependent Cox) 80.6 25.8 < 0.0001 2.5 [2.1–3.1] < 0.0001
Adjusted for SOFA at admission 89.3 11.5 0.0007 1.8 [1.4–2.2] < 0.0001
Adjusted for APACHE II at admission 108.4 19.5 < 0.0001 2.1 [1.7–2.6] < 0.0001
Adjusted for SOFA (t-d*) 101.0 7.9 0.0049 1.5 [1.1–2.0] 0.0048
Adjusted for lactate (t-d*) 138.0 35.7 < 0.0001 1.9 [1.5–2.3] < 0.0001
APACHE Acute Physiology and Chronic Health Evaluation II, bio-ADM Bioactive adrenomedullin, SOFA Sequential Organ Failure Assessment
Results are from uni- (chi-square), multi- (added chi-square), and *time-dependent Cox regression analysis. *Time-dependent analysis includes measurements
observed at baseline and day 2. n = 562 for covariates (i.e., age, gender, comorbidities [cardiac and noncardiac], diagnosis [sepsis, septic shock], lactate) model due
to missing data for time-dependent lactate, and n = 509 for models including *time-dependent SOFA score
Fig. 1 Twenty-eight-day Kaplan-Meier survival curves of low versus high biologically active adrenomedullin at admission, based on a cutoff value
of 70 pg/ml, in (a) sepsis, and (b) septic shock patients
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0.001) (Additional file 7: Figure S5) and duration of car-
diovascular drug support (Fig. 3b) (p < 0.0001). Under-
standably, patients with high bio-ADM needed
norepinephrine at admission more frequently (73% ver-
sus 42%, p < 0.0001) and at greater dose (0.4 [0.3–0.8]
versus 0.2 [0.1–0.4] μg/kg/min, p = 0.0022) than patients
with low bio-ADM (Additional file 8: Table S3). Our
analysis further revealed that patients with high bio-
ADM at admission needed more vasopressors/inotropes
over the following 7 days even if they did not have those
treatments at admission (Fig. 3c).
Regarding other organ support, patients who needed
volume resuscitation of more than 5 L over the first 2
days (Fig. 3d) (p < 0.0001) or RRT (Additional file 9:
Figure S6) or had long ICU stay (Additional file 10:
Figure S7) had much higher circulating bio-ADM levels
upon ICU admission than those patients who did not.
In agreement with the fact that serial measurements of
bio-ADM indicated survival benefit in patients who
dropped bio-ADM levels at day 2, we could demonstrate
that drop of bio-ADM over the first 2 days also preceded
the decrease of total SOFA score (p value for differences
between HH vs. HL: p < 0.0001 for all days) (Fig. 4).
Finally, using the Sepsis-3 definition of septic shock
(i.e., vasopressor use and lactate ≥ 2mmol/L [or 18 mg/dl]
despite adequate volume resuscitation [17]), our analysis
confirmed that bio-ADM upholds a strong prognostica-
tion for organ recovery and survival in AdrenOSS-1 (both
p < 0.0001) (Additional file 11: Figure S8A and B).
Discussion
The AdrenOSS-1 study was a prospective multinational
observational cohort study assessing the relationship be-
tween rapid changes in circulating bio-ADM levels in
the first 2 days and clinical outcome in ICU patients
with sepsis and septic shock. We confirmed elevated
levels of bio-ADM in septic patients and the striking
relationship between circulating bio-ADM at ICU ad-
mission, organ dysfunction, and death. We also demon-
strated that early recovery of circulating bio-ADM levels
towards normal values (i.e., < 70 pg/ml) was associated
with normalization of vascular function and better
28-day survival.
Our study found moderately elevated circulating levels
of bio-ADM at admission in sepsis and strongly elevated
bio-ADM levels in patients with septic shock, in accord-
ance with earlier reports [13, 14]. Our study also con-
firmed the marked association between bio-ADM level
at admission and short-term mortality as well as the
prognostic cutoff value of 70 pg/ml, previously described
by Marino et al. [14] and Caironi et al. [13] in both sep-
sis and septic shock (including the most recent defin-
ition [17]). Our study showed moderate prognostic value
of bio-ADM at admission using AUC but marked prog-
nostic value using Cox proportional hazards model ad-
justed for various parameters. Moreover, our study
showed that prognostic value of bio-ADM at ICU ad-
mission exerts additive value (positive changes in chi-
square) to various ICU severity scores. We described
also the association between a bio-ADM ≤ 70 pg/ml on
day 2 and very low 28-day mortality, even in patients
with initial high bio-ADM levels. The association of low
bio-ADM by day 2 with full restoration of organ func-
tion at day 7 has been shown as well.
Concerning organ dysfunction, we found a relationship
between circulating bio-ADM at ICU admission and the
subsequent need for cardiovascular and/or renal sup-
port. In our studied patients, high circulating bio-
ADM—known to have vasodilatory actions—might ac-
count for the deterioration of vascular tone and blood
pressure, as previously described [13, 14]. In the present
study, patients with high bio-ADM levels on ICU admis-
sion were more likely to need vasopressors and/or ino-
tropes either at admission or in the following days.
Moreover, they had a higher total fluid balance and
higher incidence of RRT during their ICU stay. The
ADM-induced vascular dysfunction may have contrib-
uted to this condition, although some data suggest that
high bio-AM levels might also be protective to the kid-
ney [19, 20]. Further studies are needed to elucidate the
Fig. 2 Association between the changes of biologically active
adrenomedullin (bio-ADM) levels over 48 h and mortality. HR
between high-high (HH) (levels of bio-ADM remained high) and
high-low (HL) (levels of bio-ADM declining over 48 h) 4.9 (95%
CI 2.5–9.8; HR of LL 1.1 [0.52–2.4]). Only a small number (n = 16,
2.7%; 28-day survival rate 68.8%) of patients who presented with
a low bio-ADM concentration upon admission had higher bio-
ADM level on day 2 (low-high (LH) group), which is why this
group is not represented in the figure
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exact role of bio-ADM in renal function. Of interest, the
relationship between circulating bio-ADM levels and ex-
tent of organ dysfunction, present during ICU admission,
was also true during the recovery phase. Indeed,
bio-ADM levels decreased before the improvement of
total SOFA score in our investigation. Patients with high
bio-ADM levels at ICU admission who showed a decline
towards normal bio-ADM values at day 2 were more likely
to recover vascular function and vasopressor need by day
7. By contrast, the drop in bio-ADM from ICU admission
to day 2 was associated with only limited improvement in
renal function or no improvement in lung function at day
7. These observations also warrant further exploration.
Circulating bio-ADM levels were lower in AdrenOSS-
1 than in the previously described ALBIOS cohort [13].
Indeed, in ALBIOS, septic patients were more severe, as
suggested by greater prevalence of mechanical ventila-
tion, length of stay, and short-term mortality. Likewise,
the prevalence of septic shock was greater in ALBIOS
than in AdrenOSS-1 (Additional file 12: Table S4). Of
note, different definitions of septic shock in the two
studies may have influenced study assessments.
Limitations included that in the present population
only patients with sepsis and septic shock were studied,
and results cannot be directly translated to a general
ICU population. Future studies should focus on extrapo-
lation of our results to patients with hemodynamic in-
stability related to other disease, because as study has
already been performed for cardiogenic shock [21]. Fur-
thermore, our data suggest that ADM may be associated
with myocardial function (e.g., patients with high ADM
also had significantly higher circulating natriuretic
Fig. 3 Association between biologically active adrenomedullin levels upon admission and (a) length of total organ support over the first 7 days
(p < 0.0001), (b) length of vasopressor/inotropic support over the first 7 days (p < 0.0001), (c) overall need for vasopressor support (p < 0.0001), and
(d) total fluid balance over the initial 48 h (p = 0.0001)
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peptide levels). However, data on cardiac function (e.g.,
cardiac output or left ventricular ejection fraction) were
available in only few studied patients. Finally, we used
the cut point of 70 pg/ml of circulating Bio-ADM for
validation of the previously published cut point, even
though the optimal Youden cut points in AdrenOSS-1
showed that 70 pg/ml with respect to a technical opti-
mality criterion is not optimal.
Strong points of the study are the fact that it was a
prospective international multicenter study with a large
number of patients, with a focus on mortality and organ
dysfunction. However, as is true of any observational
study, only associations can be described, and cause-
and-effect relationships cannot be deducted.
Conclusions
In this large prospective international cohort of critic-
ally ill patients admitted to the ICU with sepsis or sep-
tic shock, we confirmed the strict relationship between
high levels of bio-ADM at ICU admission and organ
dysfunction and mortality. We demonstrated that early
decrease towards the normal values of circulating
bio-ADM in the first days after ICU admission was associ-
ated with improvement of cardiovascular and renal func-
tion and was associated with very low 28-day mortality.
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